BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25383459)

  • 1. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
    Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
    Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group.
    Vargas HA; Huang EP; Lakhman Y; Ippolito JE; Bhosale P; Mellnick V; Shinagare AB; Anello M; Kirby J; Fevrier-Sullivan B; Freymann J; Jaffe CC; Sala E
    Radiology; 2017 Nov; 285(2):482-492. PubMed ID: 28641043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
    Nougaret S; Lakhman Y; Gönen M; Goldman DA; Miccò M; D'Anastasi M; Johnson SA; Juluru K; Arnold AG; Sosa RE; Soslow RA; Vargas HA; Hricak H; Kauff ND; Sala E
    Radiology; 2017 Nov; 285(2):472-481. PubMed ID: 28628421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis.
    Beer L; Sahin H; Bateman NW; Blazic I; Vargas HA; Veeraraghavan H; Kirby J; Fevrier-Sullivan B; Freymann JB; Jaffe CC; Brenton J; Miccó M; Nougaret S; Darcy KM; Maxwell GL; Conrads TP; Huang E; Sala E
    Eur Radiol; 2020 Aug; 30(8):4306-4316. PubMed ID: 32253542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
    Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
    Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
    AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
    Verhaak RG; Tamayo P; Yang JY; Hubbard D; Zhang H; Creighton CJ; Fereday S; Lawrence M; Carter SL; Mermel CH; Kostic AD; Etemadmoghadam D; Saksena G; Cibulskis K; Duraisamy S; Levanon K; Sougnez C; Tsherniak A; Gomez S; Onofrio R; Gabriel S; Chin L; Zhang N; Spellman PT; Zhang Y; Akbani R; Hoadley KA; Kahn A; Köbel M; Huntsman D; Soslow RA; Defazio A; Birrer MJ; Gray JW; Weinstein JN; Bowtell DD; Drapkin R; Mesirov JP; Getz G; Levine DA; Meyerson M;
    J Clin Invest; 2013 Jan; 123(1):517-25. PubMed ID: 23257362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival.
    Mironov O; Ishill NM; Mironov S; Vargas HA; Zheng J; Moskowitz CS; Sonoda Y; Papas RS; Chi DS; Hricak H
    Radiology; 2011 Mar; 258(3):776-84. PubMed ID: 21193598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
    Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
    AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
    Winterhoff B; Hamidi H; Wang C; Kalli KR; Fridley BL; Dering J; Chen HW; Cliby WA; Wang HJ; Dowdy S; Gostout BS; Keeney GL; Goode EL; Konecny GE
    Gynecol Oncol; 2016 Apr; 141(1):95-100. PubMed ID: 27016234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
    McIntosh LJ; O'Neill AC; Bhanusupriya S; Matalon SA; Van den Abbeele AD; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2017 Oct; 42(10):2513-2520. PubMed ID: 28429056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
    Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
    Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
    Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
    Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.
    Foster KI; Handley KF; Glassman D; Sims TT; Javadi S; Palmquist SM; Saleh MM; Fellman BM; Fleming ND; Bhosale PR; Sood AK
    Int J Gynecol Cancer; 2023 Jun; 33(6):937-943. PubMed ID: 36948527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients.
    O'Neill AC; Somarouthu B; Tirumani SH; Braschi-Amirfarzan M; Van den Abbeele AD; Ramaiya NH; Shinagare AB
    Radiology; 2017 Jan; 282(1):160-170. PubMed ID: 27479640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
    Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
    Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
    Konecny GE; Wang C; Hamidi H; Winterhoff B; Kalli KR; Dering J; Ginther C; Chen HW; Dowdy S; Cliby W; Gostout B; Podratz KC; Keeney G; Wang HJ; Hartmann LC; Slamon DJ; Goode EL
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.